טוען...
Rituximab-associated interstitial lung disease in fibrillary glomerulonephritis
Rituximab (RTX) is a chimeric monoclonal antibody against CD20+ B cells increasingly used to treat kidney disorders. RTX-induced pulmonary disease has been reported in patients treated for haematological disorders, and a few cases have been observed in patients with underlying rheumatological condit...
שמור ב:
| הוצא לאור ב: | Clin Kidney J |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Oxford University Press
2013
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4438396/ https://ncbi.nlm.nih.gov/pubmed/26064515 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sft081 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|